Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Verrica Pharmaceuticals (VRCA) FCF Margin (2021 - 2025)

Historic FCF Margin for Verrica Pharmaceuticals (VRCA) over the last 5 years, with Q3 2025 value amounting to 67.52%.

  • Verrica Pharmaceuticals' FCF Margin rose 5489300.0% to 67.52% in Q3 2025 from the same period last year, while for Sep 2025 it was 94.39%, marking a year-over-year increase of 3724400.0%. This contributed to the annual value of 805.63% for FY2024, which is 457000.0% down from last year.
  • Verrica Pharmaceuticals' FCF Margin amounted to 67.52% in Q3 2025, which was up 5489300.0% from 78.89% recorded in Q2 2025.
  • Over the past 5 years, Verrica Pharmaceuticals' FCF Margin peaked at 67.52% during Q3 2025, and registered a low of 12435.14% during Q1 2023.
  • Its 5-year average for FCF Margin is 2216.94%, with a median of 515.66% in 2023.
  • As far as peak fluctuations go, Verrica Pharmaceuticals' FCF Margin plummeted by -104989400bps in 2023, and later surged by 119137800bps in 2024.
  • Quarter analysis of 5 years shows Verrica Pharmaceuticals' FCF Margin stood at 92.47% in 2021, then crashed by -7884bps to 7382.35% in 2022, then surged by 90bps to 741.15% in 2023, then crashed by -530bps to 4669.77% in 2024, then soared by 101bps to 67.52% in 2025.
  • Its FCF Margin was 67.52% in Q3 2025, compared to 78.89% in Q2 2025 and 369.29% in Q1 2025.